RT Journal Article
T1 A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
A1 Pascual, Tomás
A1 Martin, Miguel
A1 Fernández-Martínez, Aranzazu
A1 Paré, Laia
A1 Alba, Emilio
A1 Rodríguez-Lescure, Álvaro
A1 Perrone, Giuseppe
A1 Cortés, Javier
A1 Morales, Serafín
A1 Lluch, Ana
A1 Urruticoechea, Ander
A1 González-Farré, Blanca
A1 Galván, Patricia
A1 Jares, Pedro
A1 Rodriguez, Adela
A1 Chic, Nuria
A1 Righi, Daniela
A1 Cejalvo, Juan Miguel
A1 Tonini, Giuseppe
A1 Adamo, Barbara
A1 Vidal, Maria
A1 Villagrasa, Patricia
A1 Muñoz, Montserrat
A1 Prat, Aleix
K1 PAM50
K1 breast cancer
K1 gene expression
K1 intrinsic subtype
K1 non-luminal
AB Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estrogen receptor (ER), progesterone receptor (PR) and Ki67 tumor cells, was derived in a combined cohort of 5 studies (training dataset) and tested in a combined cohort of 3 studies. The performance of NOLUS was estimated using Area Under the ROC Curve (AUC). Results: In the training dataset (n = 903) and compared to luminal disease, non-luminal disease had lower percentage of ER-positive cells (median 65.2 vs. 86.2%, p
SN 2234-943X
YR 2019
FD 2019-04-26
LK http://hdl.handle.net/10668/13987
UL http://hdl.handle.net/10668/13987
LA en
DS RISalud
RD Apr 17, 2025